Health-related quality of life assessment in haemophilia patients on prophylaxis therapy: A systematic review of results from prospective clinical trials

Haemophilia

Volumn 21, Issue 5, 2015, Pages e344-e358

  Oladapo, A O ^a   Epstein, J D ^b   Williams, E ^c   Ito, D ^a   Gringeri, A ^d   Valentino, L A ^e  

^a Baxalta US   (United States)

^b Baxalta US Inc   (United States)

^c Marinus Consulting   (United States)

^d Baxalta Innovations GmbH   (Austria)

^e RUSH UNIVERSITY   (United States)

Author keywords

Bypassing agents; FIX; FVIII; Haemophilia; HRQoL; Prophylaxis

Indexed keywords

ACTIVATED PROTHROMBIN COMPLEX; BLOOD CLOTTING FACTOR 8; BLOOD CLOTTING FACTOR 9;

CLINICAL EFFECTIVENESS; CLINICAL TRIAL (TOPIC); DISEASE ASSOCIATION; DISEASE SEVERITY; DRUG EFFICACY; HEMOPHILIA A; HEMOPHILIA B; HUMAN; OBSERVATIONAL STUDY; PATIENT ASSESSMENT; PHYSICAL ACTIVITY; PRIORITY JOURNAL; PROPHYLAXIS; QUALITY OF LIFE; REVIEW; SHORT FORM 36; SYSTEMATIC REVIEW; TREATMENT DURATION; TREATMENT OUTCOME; HEALTH; META ANALYSIS; PROSPECTIVE STUDY; QUESTIONNAIRE;

CLINICAL TRIALS AS TOPIC; HEALTH; HEMOPHILIA A; HUMANS; PROSPECTIVE STUDIES; QUALITY OF LIFE; SURVEYS AND QUESTIONNAIRES; TREATMENT OUTCOME;

EID: 84942191461     PISSN: 13518216     EISSN: 13652516     Source Type: Journal    
DOI: 10.1111/hae.12759     Document Type: Review

References (50)

1. Gringeri A, Mantovani L, Mackensen SV. Quality of life assessment in clinical practice in haemophilia treatment. Haemophilia 2006; 12(Suppl 3): 22-9.
2. Szende A, Schramm W, Flood E et al. Health-related quality of life assessment in adult haemophilia patients: a systematic review and evaluation of instruments. Haemophilia 2003; 9: 678-87.
3. Royal S, Schramm W, Berntorp E et al. Quality-of-life differences between prophylactic and on-demand factor replacement therapy in European haemophilia patients. Haemophilia 2002; 8: 44-50.
4. Klamroth R, Pollmann H, Hermans C et al. The relative burden of haemophilia A and the impact of target joint development on health-related quality of life: results from the ADVATE Post-Authorization Safety Surveillance (PASS) study. Haemophilia 2011; 17: 412-21.
5. Trippoli S, Vaiani M, Linari S, Longo G, Morfini M, Messori A. Multivariate analysis of factors influencing quality of life and utility in patients with haemophilia. Haematologica 2001; 86: 722-8.
6. Taha MY, Hassan MK. Health-related quality of life in children and adolescents with hemophilia in Basra. Southern Iraq. J Pediatr Hematol Oncol 2014; 36: 179-84.
7. Solovieva S. Clinical severity of disease, functional disability and health-related quality of life. Three-year follow-up study of 150 Finnish patients with coagulation disorders. Haemophilia 2001; 7: 53-63.
8. Poon JL, Zhou ZY, Doctor JN et al. Quality of life in haemophilia A: hemophilia Utilization Group Study Va (HUGS-Va). Haemophilia 2012; 18: 699-707.
9. Hartl HK, Reitter S, Eidher U, Ramschak H, Ay C, Pabinger I. The impact of severe haemophilia on the social status and quality of life among Austrian haemophiliacs. Haemophilia 2008; 14: 703-8.
10. Fischer K, Bom JG, Mauser-Bunschoten EP, Roosendaal G, Berg HM. Effects of haemophilic arthropathy on health-related quality of life and socio-economic parameters. Haemophilia 2005; 11: 43-8.
11. Antunes SV, Tangada S, Stasyshyn O et al. Randomized comparison of prophylaxis and on-demand regimens with FEIBA NF in the treatment of haemophilia A and B with inhibitors. Haemophilia 2013; 20: 65-72.
12. Collins P, Faradji A, Morfini M, Enriquez MM, Schwartz L. Efficacy and safety of secondary prophylactic vs. on-demand sucrose-formulated recombinant factor VIII treatment in adults with severe hemophilia A: results from a 13-month crossover study. J Thromb Haemost 2010; 8: 83-9.
13. Gringeri A, Lundin B, von Mackensen S, Mantovani L, Mannucci PM. A randomized clinical trial of prophylaxis in children with hemophilia A (the ESPRIT Study). J Thromb Haemost 2011; 9: 700-10.
14. Leissinger C, Gringeri A, Antmen B et al. Anti-inhibitor coagulant complex prophylaxis in hemophilia with inhibitors. N Engl J Med 2011; 365: 1684-92.
15. Konkle BA, Ebbesen LS, Erhardtsen E et al. Randomized, prospective clinical trial of recombinant factor VIIa for secondary prophylaxis in hemophilia patients with inhibitors. J Thromb Haemost 2007; 5: 1904-13.
16. Manco-Johnson MJ, Kempton CL, Reding MT et al. Randomized, controlled, parallel-group trial of routine prophylaxis vs. on-demand treatment with sucrose-formulated recombinant factor VIII in adults with severe hemophilia A (SPINART). J Thromb Haemost 2013; 11: 1119-27.
17. Valentino LA, Mamonov V, Hellmann A et al. A randomized comparison of two prophylaxis regimens and a paired comparison of on-demand and prophylaxis treatments in hemophilia A management. J Thromb Haemost 2012; 10: 359-67.
18. Windyga J, Lissitchkov T, Stasyshyn O et al. Pharmacokinetics, efficacy and safety of BAX326, a novel recombinant factor IX: a prospective, controlled, multicentre phase I/III study in previously treated patients with severe (FIX level <1%) or moderately severe (FIX level
19. Buchbinder D, Ragni MV. What is the role of prophylaxis in the improvement of health-related quality of life of patients with hemophilia? Hematology Am Soc Hematol Educ Program 2013; 2013: 52-5.
20. Gringeri A, Leissinger C, Cortesi PA et al. Health-related quality of life in patients with haemophilia and inhibitors on prophylaxis with anti-inhibitor complex concentrate: results from the Pro-FEIBA study. Haemophilia 2013; 19: 736-43.
21. Wyrwich K, Auguste P, vonMaltzahn R et al. Psychometric evaluation of health-related quality of life assessments from the Along and Blong hemophilia clinical trials. Presented at the 55th American Society of Hematology Annual Meeting and Exposition. 2013. Abstract number: 423. 2013.
22. Santagostino E, Lentz SR, Busk AK, Regnault A, Iorio A. Assessment of the impact of treatment on quality of life of patients with haemophilia A at different ages: insights from two clinical trials on turoctocog alfa. Haemophilia 2014; 20: 527-34.
23. Windyga J, Lin VW, Epstein JD et al. Improvement in health-related quality of life with recombinant factor IX prophylaxis in severe or moderately severe haemophilia B patients: results from the BAX326 Pivotal Study. Haemophilia 2014b; 20: 362-8.
24. Powell JS, Pasi KJ, Ragni MV et al. Phase 3 study of recombinant factor IX Fc fusion protein in hemophilia B. N Engl J Med 2013; 369: 2313-23.
25. Hoots WK, Ebbesen LS, Konkle BA et al. Secondary prophylaxis with recombinant activated factor VII improves health-related quality of life of haemophilia patients with inhibitors. Haemophilia 2008; 14: 466-75.
26. Wyrwich KW, Krishnan S, Auguste P et al. Health-related quality of life data changes from baseline using Haem-A-QoL scores in the A-LONG clinical study of recombinant factor VIII Fc fusion protein. Presented at the World Federation of Hemophilia (WFH) World Congress. 2014. Abstract no. MP-M-08. 2014.
27. Wyrwich KW, Krishnan S, Auguste P et al. Health-related quality of life data changes over time using Haem-A-QoL scores in the B-LONG clinical study of recombinant factor IX Fc fusion protein. Presented at the World Federation of Hemophilia (WFH) World Congress. 2014. Abstract no. P-M-221. 2014.
28. Hong W, Pocoski J, Raunig D, Funk S, Manco-Johnson MJ. SPINART trial 3-year results with Bayer's sucrose-formulated recombinant factor VIII: improved joint function and health-related quality of life in adults using prophylaxis. Presented at the World Federation of Hemophilia (WFH) World Congress. 2014. Abstract no. P-W-136. 2014.
29. Lentz SR, Misgav M, Ozelo M et al. Results from a large multinational clinical trial (guardian1) using prophylactic treatment with turoctocog alfa in adolescent and adult patients with severe haemophilia A: safety and efficacy. Haemophilia 2013; 19: 691-7.
30. Mahlangu J, Powell JS, Ragni MV et al. Phase 3 study of recombinant factor VIII Fc fusion protein in severe hemophilia A. Blood 2014; 123: 317-25.
31. Wu R, Sun J, Xiao J et al. A quality of life study (CHO-KLAT) of boys with severe hemophilia A in China: a comparison of on-demand to short-term prophylaxis. Haemophilia 2014; 20(Suppl 3): 97.
32. Jaeschke R, Singer J, Guyatt GH. Measurement of health status. Ascertaining the minimal clinically important difference. Control Clin Trials 1989; 10: 407-15.
33. Stasyshyn O, Antunes S, Mamonov V et al. Prophylaxis with anti-inhibitor coagulant complex improves health-related quality of life in haemophilia patients with inhibitors: results from FEIBA NF Prophylaxis Study. Haemophilia 2014; 20: 644-50.
34. von Mackensen S, Gringeri A, Siboni SM, Mannucci PM. Health-related quality of life and psychological well-being in elderly patients with haemophilia. Haemophilia 2012; 18: 345-52.
35. International Society for Pharmacoeconomics and Outcomes Research. ISPOR Quality of Life Regulatory Guidance Issues. Quality of Life Promotional and Label Claim Issues for Drugs, Biologicals, and Devices. http://www.ispor.org/workpaper/consensus/index.asp. Accessed 14 February 2014.
36. von Mackensen S, Bullinger M. Development and testing of an instrument to assess the Quality of Life of Children with Haemophilia in Europe (Haemo-QoL). Haemophilia 2004; 10(Suppl 1): 17-25.
37. Solovieva S, Santavirta N, Santavirta S, Konttinen YT. Assessing quality of life in individuals with hereditary blood coagulation disorders. Qual Life Res 2004; 13: 987-1000.
38. Riva S, Bullinger M, Amann E, von Mackensen S. Content comparison of haemophilia specific patient-rated outcome measures with the international classification of functioning, disability and health (ICF, ICF-CY). Health Qual Life Outcomes 2010; 8: 139.
39. TM). Proceedings of the 58th Annual Meeting of the Society of Thrombosis and Haemostasis Research (GTH), 12-15 February, 2014. Vienna, Austria. 2014.
40. Fischer K, van der Bom JG, Mauser-Bunschoten EP et al. The effects of postponing prophylactic treatment on long-term outcome in patients with severe hemophilia. Blood 2002; 99: 2337-41.
41. Astermark J, Petrini P, Tengborn L, Schulman S, Ljung R, Berntorp E. Primary prophylaxis in severe haemophilia should be started at an early age but can be individualized. Br J Haematol 1999; 105: 1109-13.
42. Kulkarni R, Karim FA, Glamocanin S et al. Results from a large multinational clinical trial (guardian3) using prophylactic treatment with turoctocog alfa in paediatric patients with severe haemophilia A: safety, efficacy and pharmacokinetics. Haemophilia 2013; 19: 698-705.
43. The EuroQol Group. EuroQol-a new facility for the measurement of health-related quality of life. Health Policy 1990; 16: 199-208.
44. Miners AH, Sabin CA, Tolley KH, Jenkinson C, Kind P, Lee CA. Assessing health-related quality-of-life in individuals with haemophilia. Haemophilia 1999; 5: 378-85.
45. Molho P, Rolland N, Lebrun T et al. Epidemiological survey of the orthopaedic status of severe haemophilia A and B patients in France. The French Study Group. secretariat.haemophilesaaacch.ap-hop-paris.fr. Haemophilia 2000; 6: 23-32.
46. Aznar JA, Magallon M, Querol F, Gorina E, Tusell JM. The orthopaedic status of severe haemophiliacs in Spain. Haemophilia 2000; 6: 170-6.
47. Bradley CS, Bullinger M, McCusker PJ, Wakefield CD, Blanchette VS, Young NL. Comparing two measures of quality of life for children with haemophilia: the CHO-KLAT and the Haemo-QoL. Haemophilia 2006; 12: 643-53.
48. Young NL, Bradley CS, Wakefield CD, Barnard D, Blanchette VS, McCusker PJ. How well does the Canadian Haemophilia Outcomes-Kids' Life Assessment Tool (CHO-KLAT) measure the quality of life of boys with haemophilia? Pediatr Blood Cancer 2006; 47: 305-11.
49. Rentz A, Flood E, Altisent C et al. Cross-cultural development and psychometric evaluation of a patient-reported health-related quality of life questionnaire for adults with haemophilia. Haemophilia 2008; 14: 1023-34.
50. Ware J, Kosinski M, Bjorner J. User's Manual for the SF-36v2 Health Survey. 2nd ed. Lincoln, RI: Quality Metric Incorporated, 2007.